Table 4.
Hazard ratio (95% CI) for overall survival among ovarian cancer patients according to ABO blood type
| ABO blood type |
P value for Interaction |
||||
|---|---|---|---|---|---|
| Type O | Type A | Type B | Type AB | ||
| HR (95%CI)† | HR (95%CI)† | HR (95%CI)† | HR (95%CI)† | ||
| All patients | 1.00 (Ref) | 1.05 (0.74-1.48) | 1.02 (0.72-1.44) | 0.77 (0.43-1.36) | |
| FIGO stage | 0.59 | ||||
| I-II | 1.00 (Ref) | 1.37 (0.62-3.05) | 0.94 (0.39-2.26) | 0.84 (0.18-3.90) | |
| III-IV | 1.00 (Ref) | 0.97 (0.66-1.42) | 1.01 (0.69-1.48) | 0.74 (0.40-1.37) | |
| Histological type | 0.74 | ||||
| Serous | 1.00 (Ref) | 1.11 (0.75-1.65) | 1.02 (0.69-1.52) | 0.68 (0.35-1.34) | |
| Non-serous | 1.00 (Ref) | 0.75 (0.34-1.64) | 0.96 (0.45-2.07) | 1.00 (0.32-3.12) | |
| Residual disease | 0.75 | ||||
| None detectable | 1.00 (Ref) | 1.30 (0.76-2.24) | 1.00 (0.57-1.76) | 1.04 (0.42-2.59) | |
| ≤ 1 cm | 1.00 (Ref) | 0.83 (0.42-1.64) | 0.96 (0.49-1.87) | 0.47 (0.15-1.43) | |
| > 1 cm | 1.00 (Ref) | 0.75 (0.40-1.40) | 0.72 (0.38-1.37) | 0.80 (0.28-2.31) | |
| Comorbidity | 0.57 | ||||
| Yes | 1.00 (Ref) | 1.17 (0.73-1.87) | 1.23 (0.77-1.97) | 0.65 (0.31-1.37) | |
| No | 1.00 (Ref) | 0.90 (0.54-1.49) | 0.79 (0.47-1.33) | 0.98 (0.40-2.43) | |
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.
† HRs (95% CIs) for overall survival were estimated by using multivariable proportional hazard models that were adjusted for age at diagnosis, FIGO, residual disease, performance status, ascites, and grading.